Comparing AVA™-prescribed spectacle lenses with standard prescriptions

Post Market Clinical Study to Compare Vision With Essilor® AVA™ Lenses Following AVA™ Refraction Protocol to Equivalent Lenses Following Gold Standard Refraction Protocol.

This test sees if lenses made from a new AVA™ prescription method give clearer vision and better comfort than standard lenses for adults with refractive error.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 120 (estimated)
• Ages: 18 Years to 70 Years
• Sex: All
• Sponsor: Essilor International (Industry-sponsored)
• Locations: 1 site (Bloomington, Indiana)
• Trial ID: NCT07168564 on ClinicalTrials.gov

What this trial studies

This interventional study compares two spectacle lens prescriptions produced from a new AVA™ subjective refraction protocol (with 0.01D increments and high-accuracy instrumentation) against conventional prescriptions using 0.25D steps. Participants who meet vision and health criteria will wear the assigned lenses for two weeks and report outcomes including visual acuity, comfort, satisfaction, and red-green equality on the duochrome test. The trial seeks to determine whether finer refraction and manufacturing increments produce perceptible and clinically meaningful improvements in everyday vision. Half of the analyzed population will include presbyopic participants adapted to progressive addition lenses to evaluate effects across age groups.

Who should consider this trial

Good fit: Adults aged 18–70 with a wearable pair of glasses used at least 6 hours/day, best-corrected acuity of 20/25 or better, spherical equivalent between -10.00 and +10.00 D, no binocular vision problems or significant cataract, and presbyopes adapted to progressive lenses for the presbyopic subgroup.

Not a fit: People with significant ocular disease (including cataract grade 2 or greater), binocular vision issues, those who do not wear spectacles regularly, or those outside the 18–70 age range are unlikely to benefit from this intervention.

Why it matters

Potential benefit: If successful, the approach could produce more precise prescriptions and modest but noticeable improvements in visual clarity, comfort, and patient satisfaction for eyeglass wearers.

How similar studies have performed: High-resolution digital refraction technologies and finer lens manufacturing are relatively new and prior clinical evidence is limited, so their real-world benefits remain not well established.

Eligibility criteria

Inclusion Criteria:

1. Age between 18 y/o and 70
2. Accepted and signed the consent form
3. Agree to participate in the scheduled visits
4. Best-corrected visual acuity by manifest refraction of +0.10 log MAR (20/25 Snellen) or better in each eye
5. Spherical Equivalent Refractive Error between -10.00 and 10.00 D
6. Possess current wearable and visually functional eyeglasses
7. Agree to wear the assigned frames fitted with the provided lenses for a minimum of 14 days, during 6h/day, equivalent to 42 hours of wearing a week.
8. No binocular vision issues
9. No cataract, grade 2 or greater

   Presbyope subjects: To be eligible for the presbyopic group, individuals need to be (half of the analyzed population):
10. 35-70 years of age, inclusive
11. Currently wearing and adapted to progressive addition lenses

Exclusion Criteria:

1. Less than 18 years or greater than 70 years of age
2. Does not wear spectacles at least 6 hours/day
3. Does not have a wearable pair of glasses with a prescription ≤2 years old
4. Currently or formerly a licensed optometrist, optician, or ophthalmic technician trained in refraction

Where this trial is running

Bloomington, Indiana

• Clinical Optics Research Lab @ Borish Center for Ophthalmic Research Indiana University School of Optometry Indiana University — Bloomington, Indiana, United States (Recruiting)

Study contacts

• Principal investigator: Pete Kollbaum, Professor — Indiana University
• Study coordinator: Pete Kollbaum, Professor

Conditions Ametropia; Refractive Error; Corrective eye glasses